1
|
Kassick AJ, Treat A, Tomycz N, Feasel MG, Kolber BJ, Averick S. Design, synthesis, and biological evaluation of C 6-difluoromethylenated epoxymorphinan Mu opioid receptor antagonists. RSC Med Chem 2022; 13:175-182. [PMID: 35308026 PMCID: PMC8864491 DOI: 10.1039/d1md00285f] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 10/28/2021] [Indexed: 03/12/2024] Open
Abstract
The recent widespread abuse of high potency synthetic opioids, such as fentanyl, presents a serious threat to individuals affected by substance use disorder. Synthetic opioids generally exhibit prolonged in vivo circulatory half-lives that can outlast the reversal effects of conventional naloxone-based overdose antidotes leading to a life-threatening relapse of opioid toxicity known as renarcotization. In this manuscript, we present our efforts to combat the threat of renarcotization by attempting to extend the half-life of traditional MOR antagonists through the design of novel, fluorinated 4,5-epoxymorphinans possessing increased lipophilicity. Analogues were prepared via a concise synthetic strategy highlighted by decarboxylative Wittig olefination of the C6 ketone to install a bioisosteric 1,1-difluoromethylene unit. C6-difluoromethylenated compounds successfully maintained in vitro potency against an EC90 challenge of fentanyl and were predicted to have enhanced circulatory half-life compared to the current standard of care, naloxone. Subsequent in vivo studies demonstrated the effective blockade of fentanyl-induced anti-nociception in mice.
Collapse
Affiliation(s)
- Andrew J Kassick
- Neuroscience Disruptive Research Lab, Allegheny Health Network Research Institute, Allegheny General Hospital Pittsburgh PA 15212 USA
- Neuroscience Institute, Allegheny Health Network, Allegheny General Hospital Pittsburgh PA 15212 USA
| | - Anny Treat
- Department of Neuroscience and Center for Advanced Pain Studies, University of Texas at Dallas Richardson TX 75080 USA
| | - Nestor Tomycz
- Neuroscience Institute, Allegheny Health Network, Allegheny General Hospital Pittsburgh PA 15212 USA
| | - Michael G Feasel
- Research and Technology Division, DEVCOM Chemical Biological Center Aberdeen Proving Ground MD 21010-5424 USA
| | - Benedict J Kolber
- Department of Neuroscience and Center for Advanced Pain Studies, University of Texas at Dallas Richardson TX 75080 USA
| | - Saadyah Averick
- Neuroscience Disruptive Research Lab, Allegheny Health Network Research Institute, Allegheny General Hospital Pittsburgh PA 15212 USA
- Neuroscience Institute, Allegheny Health Network, Allegheny General Hospital Pittsburgh PA 15212 USA
| |
Collapse
|
2
|
Towards identifying nicomorphine administration in doping control: synthesis of metabolites. Bioanalysis 2021; 13:1415-1425. [PMID: 34528849 DOI: 10.4155/bio-2021-0076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Aim: Nicomorphine is rapidly metabolized mainly to the biologically active 6-nicotinoyl morphine and morphine. In sport, morphine and nicomorphine use is prohibited whereas codeine use is permitted. Accredited laboratories routinely test for morphine hence must be able to distinguish morphine, as a metabolite of a prohibited substance, from that whose use is permitted. Results: Here we show a relatively simple method to synthesize the nicomorphine metabolites, 3-nicotinoyl and 6-nicotinoyl morphine, and indicate how they may be used to identify nicomorphine administration. Conclusion: This approach should help confirm that it is not codeine, an allowable analgesic in sport, that has been administered.
Collapse
|
3
|
Kassick AJ, Allen HN, Yerneni SS, Pary F, Kovaliov M, Cheng C, Pravetoni M, Tomycz ND, Whiting DM, Nelson TL, Feasel M, Campbell PG, Kolber B, Averick S. Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone. ACS APPLIED BIO MATERIALS 2019; 2:3418-3428. [PMID: 31497753 PMCID: PMC6731033 DOI: 10.1021/acsabm.9b00380] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The opioid epidemic currently plaguing the United States has been exacerbated by an alarming rise in fatal overdoses as a result of the proliferated abuse of synthetic mu opioid receptor (MOR) agonists, such as fentanyl and its related analogues. Attempts to manage this crisis have focused primarily on widespread distribution of the clinically approved opioid reversal agent naloxone (Narcan); however, due to the intrinsic metabolic lability of naloxone, these measures have demonstrated limited effectiveness against synthetic opioid toxicity. This work reports a novel polymer-based strategy to create a long-acting formulation of naloxone with the potential to address this critical issue by utilizing covalent nanoparticle (cNP) drug delivery technology. Covalently loaded naloxone nanoparticles (Nal-cNPs) were prepared via the naloxone-initiated, ring-opening polymerization (ROP) of l-lactide in the presence of a bifunctional thiourea organocatalyst with subsequent precipitation of the resulting naloxone-poly(l-lactic acid) polymer. This protocol afforded well-defined nanoparticles possessing a drug loading of approximately 7% w/w. The resulting Nal-cNPs demonstrated excellent biocompatibility, while exhibiting sustained linear release kinetics in vitro and blocking the effects of high dose (10 mg/kg) acute morphine for up to 98 h in an in vivo rodent model of neuropathic pain.
Collapse
Affiliation(s)
- Andrew J. Kassick
- Neuroscience Disruptive Research Lab, Allegheny Health Network Research Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, United States
- Neuroscience Institute, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, United States
| | - Heather N. Allen
- Department of Biological Sciences and Chronic Pain Research Consortium, Duquesne University, Pittsburgh, Pennsylvania 15282, United States
| | - Saigopalakrishna S. Yerneni
- Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, United States
| | - Fathima Pary
- Department of Chemistry, Oklahoma State University, Stillwater, Oklahoma 74078, United States
| | - Marina Kovaliov
- Neuroscience Disruptive Research Lab, Allegheny Health Network Research Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, United States
- Neuroscience Institute, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, United States
| | - Cooper Cheng
- Neuroscience Institute, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, United States
| | - Marco Pravetoni
- Department of Pharmacology, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota 55455, United States
| | - Nestor D. Tomycz
- Neuroscience Institute, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, United States
| | - Donald M. Whiting
- Neuroscience Institute, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, United States
| | - Toby L. Nelson
- Department of Chemistry, Oklahoma State University, Stillwater, Oklahoma 74078, United States
| | - Michael Feasel
- Chemical Biological Center, APG, U.S. Army Combat Capabilities Development Command, Edgewood, Maryland 21010, United States
| | - Phil G. Campbell
- Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, United States
- Engineering and Engineering Research Accelerator, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, United States
| | - Benedict Kolber
- Department of Biological Sciences and Chronic Pain Research Consortium, Duquesne University, Pittsburgh, Pennsylvania 15282, United States
| | - Saadyah Averick
- Neuroscience Disruptive Research Lab, Allegheny Health Network Research Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, United States
- Neuroscience Institute, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, United States
| |
Collapse
|
4
|
Ahonen TJ, Rinne M, Grutschreiber P, Mätlik K, Airavaara M, Schaarschmidt D, Lang H, Reiss D, Xhaard H, Gaveriaux-Ruff C, Yli-Kauhaluoma J, Moreira VM. Synthesis of 7β-hydroxy-8-ketone opioid derivatives with antagonist activity at mu- and delta-opioid receptors. Eur J Med Chem 2018; 151:495-507. [DOI: 10.1016/j.ejmech.2018.02.074] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Revised: 01/31/2018] [Accepted: 02/22/2018] [Indexed: 10/17/2022]
|
5
|
Physico-chemical profiling of semisynthetic opioids. J Pharm Biomed Anal 2016; 135:97-105. [PMID: 28012310 DOI: 10.1016/j.jpba.2016.12.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Revised: 12/07/2016] [Accepted: 12/10/2016] [Indexed: 11/23/2022]
Abstract
Species-specific acid-base and partition equilibrium constants were experimentally determined for the therapeutically important semisynthetic opioid receptor agonist hydromorphone, dihydromorphine, and mixed agonist-antagonist nalorphine and nalbuphine. The acid-base microequilibria were characterized by combining pH-potentiometry and deductive methods using synthesized auxiliary compounds. Independent of the pH, there are approximately 4.8 times as many zwitterionic microspecies than non-charged ones in nalbuphine solutions, while for nalorphine it is the non-charged form that predominates by the same ratio. The non-charged microspecies is the dominant one also in the case of hydromorphone, although its concentration exceeds only 1.3 times that of its zwitterionic protonation isomer. The pH-independent partition coefficients of the individual microspecies were determined by a combination of experimentally measured, pH-dependent, conditional distribution constants and a custom-tailored evaluation method, using highly similar auxiliary compounds. The pH-independent contribution of the zwitterionic microspecies to the distribution constant is 1380, 1070, 3160 and 72,440 times smaller than that of the inherently more lipophilic non-charged one for hydromorphone, dihydromorphine, nalbuphine and nalorphine, respectively.
Collapse
|